Table 3.
Propensity score analysis results 1: Survival impact across quintiles based on the propensity to receive chemotherapy among patients with metastatic non-small cell lung cancer, who survived at least 3 months after their cancer diagnosis (n = 7,879)
| Analysis | Variables | HR | (95%CI) | P-value |
|---|---|---|---|---|
| Stratified analysis | ||||
| Lowest quintile of PS* | No chemotherapy | 1.00 | - | - |
| Chemotherapy | 0.82 | (0.73, 0.93) | < 0.01 | |
| Second quintile of PS | No chemotherapy | 1.00 | - | - |
| Chemotherapy | 0.77 | (0.69, 0.85) | < 0.001 | |
| Third quintile of PS | No chemotherapy | 1.00 | - | - |
| Chemotherapy | 0.81 | (0.74, 0.90) | < 0.001 | |
| Fourth quintile of PS | No chemotherapy | 1.00 | - | - |
| Chemotherapy | 0.85 | (0.77, 0.93) | < 0.01 | |
| Highest quintile of PS† | No chemotherapy | 1.00 | - | - |
| Chemotherapy | 0.73 | (0.66, 0.81) | < 0.001 | |
| Multiple Cox regression adjustment using the PS | No chemotherapy | 1.00 | - | - |
| Chemotherapy | 0.76 | (0.71, 0.82) | < 0.001 |
Abbreviation: HR, hazard ratio; CI, confidence interval; PS, propensity score.
* Patients are least likely to receive "chemotherapy."
† Patients are most likely to receive "chemotherapy."